DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/39jjcf/cancer_drugs_in) has announced the addition of the "Cancer Drugs in the FDA Fast Lane Drug Pipeline Update 2013" report to their offering.
The US Food and Drug Administration (FDA) has throughout the last decades added four major ways it can speed up the market approval of new drugs, ranging from Fast track (1988), Accelerated approval (1992), Priority review (1992) to the most recent Breakthrough therapy (2012).
This pipeline update, Cancer Drugs in the FDA Fast Lane, gives a thorough account on which cancer drugs the FDA has chosen to favor for one or more of the above mentioned fast lane programs. Each drug carries in-depth information detailing overall developmental progression for each drug, targets, pathways, indications etc. helping you to analyze trends and facts on what could tip the FDA in your favor. Now be warned this is not really an exact science as Percy Ivy, associate chief of the Investigational Drug Branch at the US National Cancer Institute's Cancer Therapy Evaluation Program in Rockville, Maryland, expressed it by likens the definition of a breakthrough drug to US Supreme Court Justice Potter Stewart's notorious 1964 definition of pornography: You're just going to know it when you see it, Ivy says.
There are today 114 companies plus partners developing 114 cancer drugs in the FDA fast lane drugs in 771 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 45 drugs.
This report lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 126 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 124 out of the 124 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application by 45 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Reasons To Buy
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines
For more information visit http://www.researchandmarkets.com/research/39jjcf/cancer_drugs_in
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.